SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.

Eric Horlick, Clifford J. Kavinsky, Zahid Amin, Konstantinos Dean Boudoulas, John D. Carroll, Ziyad M. Hijazi, Dana Leifer, Helmi L. Lutsep, John F. Rhodes, Jonathan M. Tobis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Until recently, evidence to support Patent Foramen Ovale (PFO) closure for secondary prevention of recurrent stroke has been controversial. Publication of high-quality evidence from randomized clinical trials and the subsequent FDA approval of two devices for percutaneous PFO closure is expected to increase the volume of PFO closure procedures not only in the United States but worldwide. As this technology is disseminated broadly to the public, ensuring the safe and efficacious performance of PFO closure is essential to mitigate risk and avoid unnecessary procedures. This document, prepared by a multi-disciplinary writing group convened by the Society for Cardiovascular Angiography and Interventions and including representatives from the American Academy of Neurology, makes recommendations for institutional infrastructure and individual skills necessary to initiate and maintain an active PFO/stroke program, with emphasis on shared decision making and patient-centered care.

Original languageEnglish (US)
Pages (from-to)859-874
Number of pages16
JournalCatheterization and Cardiovascular Interventions
Volume93
Issue number5
DOIs
StatePublished - Apr 1 2019

Fingerprint

Patent Foramen Ovale
Secondary Prevention
Consensus
Stroke
Device Approval
Unnecessary Procedures
Patient-Centered Care
Publications
Decision Making
Randomized Controlled Trials
Neurologists
Technology

Keywords

  • ASD/PDA/PFO
  • closure
  • comparative effectiveness/patient centered outcomes research
  • evidence-based medicine
  • structural heart disease intervention

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke : The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. / Horlick, Eric; Kavinsky, Clifford J.; Amin, Zahid; Dean Boudoulas, Konstantinos; Carroll, John D.; Hijazi, Ziyad M.; Leifer, Dana; Lutsep, Helmi L.; Rhodes, John F.; Tobis, Jonathan M.

In: Catheterization and Cardiovascular Interventions, Vol. 93, No. 5, 01.04.2019, p. 859-874.

Research output: Contribution to journalArticle

Horlick, Eric ; Kavinsky, Clifford J. ; Amin, Zahid ; Dean Boudoulas, Konstantinos ; Carroll, John D. ; Hijazi, Ziyad M. ; Leifer, Dana ; Lutsep, Helmi L. ; Rhodes, John F. ; Tobis, Jonathan M. / SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke : The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. In: Catheterization and Cardiovascular Interventions. 2019 ; Vol. 93, No. 5. pp. 859-874.
@article{c53bab62b3f4467c84afaa022ab81cbd,
title = "SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.",
abstract = "Until recently, evidence to support Patent Foramen Ovale (PFO) closure for secondary prevention of recurrent stroke has been controversial. Publication of high-quality evidence from randomized clinical trials and the subsequent FDA approval of two devices for percutaneous PFO closure is expected to increase the volume of PFO closure procedures not only in the United States but worldwide. As this technology is disseminated broadly to the public, ensuring the safe and efficacious performance of PFO closure is essential to mitigate risk and avoid unnecessary procedures. This document, prepared by a multi-disciplinary writing group convened by the Society for Cardiovascular Angiography and Interventions and including representatives from the American Academy of Neurology, makes recommendations for institutional infrastructure and individual skills necessary to initiate and maintain an active PFO/stroke program, with emphasis on shared decision making and patient-centered care.",
keywords = "ASD/PDA/PFO, closure, comparative effectiveness/patient centered outcomes research, evidence-based medicine, structural heart disease intervention",
author = "Eric Horlick and Kavinsky, {Clifford J.} and Zahid Amin and {Dean Boudoulas}, Konstantinos and Carroll, {John D.} and Hijazi, {Ziyad M.} and Dana Leifer and Lutsep, {Helmi L.} and Rhodes, {John F.} and Tobis, {Jonathan M.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1002/ccd.28111",
language = "English (US)",
volume = "93",
pages = "859--874",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke

T2 - The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.

AU - Horlick, Eric

AU - Kavinsky, Clifford J.

AU - Amin, Zahid

AU - Dean Boudoulas, Konstantinos

AU - Carroll, John D.

AU - Hijazi, Ziyad M.

AU - Leifer, Dana

AU - Lutsep, Helmi L.

AU - Rhodes, John F.

AU - Tobis, Jonathan M.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Until recently, evidence to support Patent Foramen Ovale (PFO) closure for secondary prevention of recurrent stroke has been controversial. Publication of high-quality evidence from randomized clinical trials and the subsequent FDA approval of two devices for percutaneous PFO closure is expected to increase the volume of PFO closure procedures not only in the United States but worldwide. As this technology is disseminated broadly to the public, ensuring the safe and efficacious performance of PFO closure is essential to mitigate risk and avoid unnecessary procedures. This document, prepared by a multi-disciplinary writing group convened by the Society for Cardiovascular Angiography and Interventions and including representatives from the American Academy of Neurology, makes recommendations for institutional infrastructure and individual skills necessary to initiate and maintain an active PFO/stroke program, with emphasis on shared decision making and patient-centered care.

AB - Until recently, evidence to support Patent Foramen Ovale (PFO) closure for secondary prevention of recurrent stroke has been controversial. Publication of high-quality evidence from randomized clinical trials and the subsequent FDA approval of two devices for percutaneous PFO closure is expected to increase the volume of PFO closure procedures not only in the United States but worldwide. As this technology is disseminated broadly to the public, ensuring the safe and efficacious performance of PFO closure is essential to mitigate risk and avoid unnecessary procedures. This document, prepared by a multi-disciplinary writing group convened by the Society for Cardiovascular Angiography and Interventions and including representatives from the American Academy of Neurology, makes recommendations for institutional infrastructure and individual skills necessary to initiate and maintain an active PFO/stroke program, with emphasis on shared decision making and patient-centered care.

KW - ASD/PDA/PFO

KW - closure

KW - comparative effectiveness/patient centered outcomes research

KW - evidence-based medicine

KW - structural heart disease intervention

UR - http://www.scopus.com/inward/record.url?scp=85063998786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063998786&partnerID=8YFLogxK

U2 - 10.1002/ccd.28111

DO - 10.1002/ccd.28111

M3 - Article

C2 - 30896894

AN - SCOPUS:85063998786

VL - 93

SP - 859

EP - 874

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 5

ER -